TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05008848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Participate in schedule gradual reduction program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive cessation support messages
Study: NCT05210699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Flavor variant P1213616 of a 1.5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum
Study: NCT05977309

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Topical ozone therapy
Description: the topical ozone therapy group received a concentration of 30 mg/L at a frequency of 30 minutes per day for 30 days. Participants received ozone therapy topically every three days for eight treatments.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topical ozone therapy
Description: the topical ozone therapy group received a concentration of 30 mg/L at a frequency of 30 minutes per day for 30 days. Participants received ozone therapy topically every three days for eight treatments.
Study: NCT05875636

Intervention type: OTHER
Intervention: Esophagogastroduodenoscopy
Description: All patients will undergo an esophagogastroduodenoscopy per standard of care, as scheduled.

Intervention type: OTHER
Intervention: Esophagogastroduodenoscopy
Description: All patients will undergo an esophagogastroduodenoscopy per standard of care, as scheduled.
Study: NCT05678205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-201
Description: NK Cell Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-201
Description: NK Cell Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-201
Description: NK Cell Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-201
Description: NK Cell Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy
Study: NCT05562076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the spot stent(ZENFLEX ® Pinto) system
Description: the spot stent(ZENFLEX ® Pinto) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the bare stent( Everflex) system
Description: the bare stent( Everflex) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
Study: NCT05652946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tyromotion, Fourier Intelligence, Thera-Trainer, EKSO Bionics
Description: Participants to receive at least 5 sessions with advanced rehabilitation technology including at least one, or multiple, of the following devices: Amadeo, Diego, Myro, Arm Motus EMU, Pelma Motus, Tigo, Balo, EKSO NR. Sessions are 45 (+/- 5) minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard inpatient rehabilitation therapy
Description: Standard inpatient rehabilitation therapy without advanced rehabilitation technology
Study: NCT01054287

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No falls prevention intervention
Study: NCT05470101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-333
Description: ITI-333 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-333
Description: ITI-333 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-333
Description: ITI-333 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-333
Description: ITI-333 oral solution
Study: NCT06292754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnesium pin in additional to the suture anchor
Description: magnesium pin in additional to the suture anchor used routinely in clinical practice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine suture anchor
Description: routine suture anchor for the treatment-as-usual
Study: NCT04736368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EDIP Diet Suggestions
Description: CD participants will receive EDIP diet suggestions after random allocation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: diet guidance
Description: Control group will be given diet guidance according to routine experience under the participant's request.
Study: NCT05281991

Intervention type: DEVICE
Intervention: Doppler ultrasonography
Description: color flow Doppler ultrasonography

Intervention type: DEVICE
Intervention: Tsui test
Description: The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
Study: NCT05392855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom driven performance of airway clearance
Description: Perform symptom driven/intermittent airway clearance therapy with frequency based off of patient's daily symptoms including mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous daily performance of airway clearance
Description: Continue run-in protocol of twice daily airway clearance using twice daily mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
Study: NCT05018208

Intervention type: OTHER
Intervention: Computer-Assisted Intervention
Description: Use smartphone app

Intervention type: OTHER
Intervention: Computer-Assisted Intervention
Description: Use smartphone app

Intervention type: PROCEDURE
Intervention: Patient Monitoring
Description: Wear Biofourmis wearable device(s)

Intervention type: PROCEDURE
Intervention: Patient Monitoring
Description: Wear Biofourmis wearable device(s)

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT05308472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-1459
Description: Oral dose level 1, once a day for 120 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-1459
Description: Oral dose level 2, once a day for 120 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose, once a day for 120 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-1459
Description: Oral dose level 1, once a day for up to 8 months
Study: NCT05978960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition and resistance training exercise intervention
Description: 3 month 2-3 times/week, 60 min exercise regimen utilizes compound movements to focus on body composition, strength, and mobility. Classes are run by certified strength and conditioning specialists and adjusted for linear progression and safety, progressing from compound to isolated movements to maximize safety.~The nutrition intervention focuses on dietary quality by following a healthy low-carbohydrate diet, focusing on nutrient dense foods high and avoiding processed foods and simple carbohydrates to keep totals under 100g/day. Participants will be advised to eat vegetables, avoid snacking, cook all meals with family and friends, avoid eating on the run, and focus on whole foods that require preparation. Calculations and quantification of calories will be avoided, while protein consumption goals are 1.3-1.8 g/kg per. Dietary strategy will be continuously discussed during exercise sessions and the PI will have twice monthly meetings with participants.
Study: NCT04958044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Gluconate
Description: Calcium electroporation
Study: NCT05985408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: left ventricular septal pacing
Description: For left bundle branch pacing (LBBP) failure cases, use left ventricular septal pacing instead of LBBP; others were same as traditional CRT.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: right ventricular apical pacing
Description: For left bundle branch pacing (LBBP) failure cases, use right ventricular apical pacing instead of LBBP; others were same as traditional CRT.
Study: NCT06014372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Upon confirming eligibility based on inclusion criteria and obtaining signed informed consent, the patient will be administered Envafolimab at a dose of 300mg every 3 weeks (Q3W) for a total of 4 cycles, starting on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envafolimab
Description: Upon confirming eligibility based on inclusion criteria and obtaining signed informed consent, the patient will be administered Envafolimab at a dose of 300mg every 3 weeks (Q3W) for a total of 4 cycles, starting on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPEOX
Description: The neoadjuvant treatment regimen will consist of Oxaliplatin at a dose of 130mg/m2, administered intravenously over a period of more than 2 hours on Day 1, every 3 weeks; and Capecitabine at a dose of 1000mg/m2, orally, twice daily from Day 1 to Day 14, every 3 weeks, for a total of 4 cycles.
Study: NCT05866575

Intervention type: OTHER
Group type: OTHER
Intervention: escitalopram
Description: Patients will receive an antidepressant strategy : escitalopram. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.

Intervention type: OTHER
Group type: OTHER
Intervention: vortioxetine
Description: Patients will receive an antidepressant strategy : vortioxetine. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the treatment strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
Study: NCT05008848

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive NCI's Clearing the Air booklet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05308264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R906289 Monosodium (R289 Na)
Description: Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd,500 mg PO qd, 750 mg PO qd, 1000 mg PO qd)
Study: NCT04945551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: 12 weeks intervention period consisting of aerobic exercise training 3 sessions/week, 45 min/session. All training sessions are supervised. Aerobic training is conducted as ergometer bicycle training at an intensity of 70% of maximal oxygen uptake (x2/wk.) and rowing ergometer exercise at 70% of maximal heart rate (x1/wk.). In week 3, 6 and 9 VO2 max is measured to ensure sufficient adjustment of the workload during the training sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: 12 weeks intervention period consisting of aerobic exercise training 3 sessions/week, 45 min/session. All training sessions are supervised. Aerobic training is conducted as ergometer bicycle training at an intensity of 70% of maximal oxygen uptake (x2/wk.) and rowing ergometer exercise at 70% of maximal heart rate (x1/wk.). In week 3, 6 and 9 VO2 max is measured to ensure sufficient adjustment of the workload during the training sessions.
Study: NCT05745779

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c, Vitamin D, Vitamin B12
Description: Serum HbA1c, Vitamin D, Vitamin B12 values of the patients who applied for gingival treatment in the last 3 months from the date of application were found from the hospital archive and serum was not taken from the patients again for the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c, Vitamin D, Vitamin B12
Description: Serum HbA1c, Vitamin D, Vitamin B12 values of the patients who applied for gingival treatment in the last 3 months from the date of application were found from the hospital archive and serum was not taken from the patients again for the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c, Vitamin D, Vitamin B12
Description: Serum HbA1c, Vitamin D, Vitamin B12 values of the patients who applied for gingival treatment in the last 3 months from the date of application were found from the hospital archive and serum was not taken from the patients again for the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c, Vitamin D, Vitamin B12
Description: Serum HbA1c, Vitamin D, Vitamin B12 values of the patients who applied for gingival treatment in the last 3 months from the date of application were found from the hospital archive and serum was not taken from the patients again for the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c, Vitamin D, Vitamin B12
Description: Serum HbA1c, Vitamin D, Vitamin B12 values of the patients who applied for gingival treatment in the last 3 months from the date of application were found from the hospital archive and serum was not taken from the patients again for the study.
Study: NCT06371053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Intervention
Description: The intervention includes Cognitive Training: Activities targeting memory, attention, language, and executive functions to maintain cognitive abilities. This could involve cognitive games, memory exercises, and daily tasks.~Life Skills Training: Assistance in maintaining or relearning daily life skills such as personal hygiene, dressing, eating, and household chores. This could be through structured training programs and daily guidance.~Physical Exercise: Providing appropriate physical activities and exercises to maintain physical health and function, including walking, balance training, and light strength training.~Social Support: Organizing social activities and support groups to facilitate interaction and reduce social isolation and loneliness.~Emotional Support: Offering mental health support and psychosocial services to help individuals cope with emotional challenges such as anxiety and depression.
Study: NCT04776499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propylthiouracil, Riociguat, Perphenazine
Description: Administration of propylthiouracil, riociguat, and perphenazine in combination~Investigational medicinal product (IMP):~Propylthiouracil: 100 mg, Riociguat: 1 mg, Perphenazine: 16 mg
Study: NCT06187727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin
Description: After primary PCI, Henggliflozin or Placebo was administered within 24 hours, followed by daily oral administration until 6 months post-acute myocardial infarction.
Study: NCT06043076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Active iTBS will be applied using a butterfly figure-of-eight C-B60 coil connected to MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
Study: NCT05801380

Intervention type: DRUG
Intervention: AChE inhibitor monotherapy
Description: This is a drug treatment using Donepezil only

Intervention type: DRUG
Intervention: AChE inhibitor and NMDA receptor antagonist combination therapy
Description: This is a drug treatment combining Donepezil and Memantine
Study: NCT05433051

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: buccal miniscrew and TPA
Description: intrusion of molars

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: vertical holding appliance
Description: intrusion of molars
Study: NCT06043076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Active iTBS will be applied using a butterfly figure-of-eight C-B60 coil connected to MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham iTBS will be applied using acoustic stimulation of a second coil behind the participant's head

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham iTBS will be applied using acoustic stimulation of a second coil behind the participant's head
Study: NCT05427539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST LENS
Description: AO1DfA manufactured with PG hydration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST LENS
Description: AO1DfA manufactured with PG hydration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL LENS
Description: AO1DfA manufactured with IPA hydration
Study: NCT05940207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-Bandages
Description: A hydrogen-peroxide generating e-bandage for wound infection and treatment and prevention. Each e-bandage is composed of three electrodes - a working, a counter, and a reference electrode. Cotton fabric physically separates electrodes. Constant (regulated) generation of low-concentrations of hydrogen peroxide happens on the working electrode, which is in contact with the skin covered with a hydrogel layer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-Bandages
Description: A hydrogen-peroxide generating e-bandage for wound infection and treatment and prevention. Each e-bandage is composed of three electrodes - a working, a counter, and a reference electrode. Cotton fabric physically separates electrodes. Constant (regulated) generation of low-concentrations of hydrogen peroxide happens on the working electrode, which is in contact with the skin covered with a hydrogel layer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-Bandages
Description: A hydrogen-peroxide generating e-bandage for wound infection and treatment and prevention. Each e-bandage is composed of three electrodes - a working, a counter, and a reference electrode. Cotton fabric physically separates electrodes. Constant (regulated) generation of low-concentrations of hydrogen peroxide happens on the working electrode, which is in contact with the skin covered with a hydrogel layer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-Bandages
Description: A hydrogen-peroxide generating e-bandage for wound infection and treatment and prevention. Each e-bandage is composed of three electrodes - a working, a counter, and a reference electrode. Cotton fabric physically separates electrodes. Constant (regulated) generation of low-concentrations of hydrogen peroxide happens on the working electrode, which is in contact with the skin covered with a hydrogel layer.
Study: NCT05511051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fruquintinib
Description: Fruquintinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: HAIC
Study: NCT05427539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL LENS
Description: AO1DfA manufactured with IPA hydration
Study: NCT05220280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Oral imatinib 400 mg tablet once a day for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab is administered as a single IV infusion with the proposed dosing schedule of 5 mg/kg body weight.
Study: NCT05007470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL #3 112.5 Capsule
Description: VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains: Four strains of Lactobacillus (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus delbrueckii subspecies bulgaricus), three strains of Bifidobacterium (Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), and one strain of Streptococcus (Streptococcus salivarius subspecies thermophilus).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg sugar
Study: NCT05826418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MEND diet
Description: Participants will be asked to adhere to their randomized MEND diet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: mNICE diet
Description: Participants will be asked to adhere to their randomized mNICEdiet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
Study: NCT06102135

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Peptamen 1.3 PHGG
Description: The amount of tube feed will be assess by the health Care Professional.
Study: NCT06490068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC004+Toripalimab
Description: LTC004 on D1 of Week 1 and D1 of week 3. IV,90μg/kg. Beginning at week 5, all subjects will receive LTC004 in combination with Toripalimab.~LTC004:D3,iv,45μg/kg,Q3W. Toripalimab:D1,iv,240mg,Q3W.